Trivora 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Patients calling about Trivora 28 Day availability issues are presenting a real clinical challenge in 2026. While the medication is not on the FDA's official shortage list, localized pharmacy stocking gaps — driven largely by the downstream effects of the Enpresse-28 discontinuation — are resulting in oral contraceptive access disruptions that put patients at risk of unintended pregnancy. This guide provides prescribers with the clinical context and practical strategies needed to manage these situations effectively.

Clinical Background: What Is Trivora 28 Day?

Trivora-28 is a triphasic combined oral contraceptive (COC) containing levonorgestrel and ethinyl estradiol. The formulation delivers three distinct hormone phases across 21 active tablets: Phase 1 (6 tablets): 0.05 mg LNG / 0.03 mg EE; Phase 2 (5 tablets): 0.075 mg LNG / 0.04 mg EE; Phase 3 (10 tablets): 0.125 mg LNG / 0.03 mg EE; followed by 7 inert placebo tablets. It is currently manufactured by Mayne Pharma and is a generic of the original Triphasil-28.

Trivora-28 is FDA-approved solely for contraception. Like all COCs, it is not a controlled substance and can be prescribed by any licensed prescriber, including OB/GYNs, family medicine physicians, internists, nurse practitioners, and physician assistants.

Why Is Trivora 28 Day Difficult to Find in 2026?

The availability challenge stems primarily from three supply-chain factors:

1. Enpresse-28 discontinuation. Teva discontinued Enpresse-28 following the closure of its Irvine, CA manufacturing facility in 2022. Enpresse and Trivora are AB-rated equivalents with identical active ingredients. As Enpresse exited the market, prescriptions were redirected to Trivora-28, creating a demand surge that many pharmacies were unprepared to absorb.
2. NDC-based ordering systems. Chain pharmacies frequently order by specific NDC codes. A pharmacy whose system was configured to order Enpresse-28 by Teva's NDC will show no inventory even if Mayne Pharma's Trivora-28 is fully available through the same wholesaler. This is a systems issue, not a supply issue.
3. Triphasic deprioritization. Triphasic formulations represent a smaller share of COC prescriptions than monophasic pills, leading many chain pharmacies to stock them at lower quantities and reorder frequencies. Small surges in demand can quickly exhaust local inventory.

Clinical Implications: Why Oral Contraceptive Gaps Matter

Any gap in combined oral contraceptive use carries risk. The clinical concern is straightforward: each missed active tablet reduces hormonal suppression of ovulation. A gap of more than 7 days can allow follicle development and ovulation to resume. Patients who delay filling because their usual pharmacy is out of stock and don't immediately seek an alternative are at real risk of unintended pregnancy.

When counseling patients experiencing availability issues, emphasize: (1) they should not skip pills while searching; (2) you can provide a prescription for an equivalent generic or alternative; and (3) backup contraception is recommended during any transition.

Prescribing Strategies to Minimize Availability Gaps

The following prescribing practices can significantly reduce the likelihood of a patient experiencing a contraceptive gap due to stocking issues:

• Write prescriptions generically. Prescribing "Levonorgestrel/Ethinyl Estradiol 0.050-0.030 mg / 0.075-0.040 mg / 0.125-0.030 mg triphasic 28-day" — with substitution permitted — maximizes the pharmacist's flexibility to fill with any AB-rated equivalent in stock.
• Prescribe 90-day supplies. A 90-day supply reduces refill frequency and gives the patient more time to locate stock if a refill is needed.
• Have a clear substitution plan ready. Pre-discuss with patients that Levonest or Myzilra are clinically equivalent and can be substituted if needed.
• Consider mail-order for patients with recurring issues. Mail-order pharmacies often maintain broader generic inventory and can deliver 90-day supplies directly to patients.

Recommended Substitution Hierarchy for Trivora 28 Day

1. Levonest 28 or Myzilra 28 — AB-rated equivalents; identical active ingredients and triphasic schedule. No clinical adjustment period expected. No new backup contraception required if started immediately.
2. Levora 0.15/30 or Altavera — Monophasic levonorgestrel/EE. Same hormones, simplified dosing. Recommend 7-day backup. Some patients may note cycle regulation differences in cycle 1.
3. Tri-Sprintec or Tri-Previfem — Triphasic norgestimate/EE. Different progestin with a generally favorable side-effect profile. Recommend 7-day backup and counsel about potential adjustment symptoms (breakthrough bleeding, mild headache) for 1-3 cycles.

Resources to Help Your Patients Find Trivora 28 Day

For providers who want to help patients locate specific medications at nearby pharmacies, medfinder for Providers allows you to search real-time pharmacy availability by location. Patients can also use medfinder directly to find which pharmacies near them can fill their prescription.

See also: How to Help Your Patients Find Trivora 28 Day in Stock: A Provider's Guide.